針對去勢敏感性攝護腺癌病人
白蛋白濃度高低與雄性素剝奪療法反應之關聯
李明儒2,3耿俊閎1,2,3,4
1Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA；2高雄市立小港醫院 泌尿部；3高雄醫學大學附設醫院 泌尿部；
4高雄醫學大學 臨床醫學研究所
Higher albumin levels are associated with better ADT responses in men with metastatic hormone sensitive prostate cancer
Ming-Ru, Lee2,3、Jiun-Hung, Geng1,2,3,4
1Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA,2Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan, 3Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 4Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Purpose: We tested the association of serum albumin levels during the course of androgen deprivation therapy with the risk of progression to castration resistant prostate cancer (CRPC).
Materials and Methods: We identified 173 men with metastatic castration-sensitive prostate cancer treated with first line androgen deprivation therapy (ADT) from 1996 to 2013 and had available serum albumin data during ADT. Cox proportional hazards models were used to test associations between serum albumin level and the risk of CRPC while adjusting for potential confounders.
Results: Median follow up after androgen deprivation therapy was 56 months. CRPC developed in 120 men. On multivariable analysis, higher serum albumin level (more than 3.5g/dl vs less than 3.5g/dl) was associated with a decreased risk of progression to castration resistant prostate cancer (HR 0.487, 95% CI 0.313-0.758).
Conclusions: Among men with metastatic castration-sensitive prostate cancer who started androgen deprivation therapy, a higher serum albumin during the treatment was associated with risks of decreased CRPC. Further studies are needed to explore a potential role for albumin in prostate cancer progression after androgen deprivation therapy and if nutrition supplements of albumin could decrease progression.